Delving into the Latest Updates on Zibotentan/Dapagliflozin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

ETA x SGLT2

Mechanism

ETA antagonists(Endothelin receptor type A antagonists), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)

Therapeutic Areas

Urogenital DiseasesDigestive System Disorders

Active Indication

Chronic Kidney DiseasesProteinuriaLiver Cirrhosis

Inactive Indication-

Originator Organization

AstraZeneca PLC

Active Organization

AstraZeneca AB

AstraZeneca PLCAstraZeneca Global R&D (China) Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H16N6O4S

InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-N

CAS Registry186497-07-4

View All Structures (2)

This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patients with cirrhosis.

Start Date15 Feb 2024

Sponsor / Collaborator

AstraZeneca PLC

NCT05570305

/ Enrolling by invitationPhase 2

A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria: a Randomized Double Blind Cross-Over Trial

The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.

Start Date06 Oct 2022

Sponsor / Collaborator

University Medical Center Groningen

[+1]

100 Clinical Results associated with Zibotentan/Dapagliflozin

Login to view more data

100 Translational Medicine associated with Zibotentan/Dapagliflozin

Login to view more data

100 Patents (Medical) associated with Zibotentan/Dapagliflozin

Login to view more data

100 Deals associated with Zibotentan/Dapagliflozin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Proteinuria	Phase 3	NO	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	CN	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	MX	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	TH	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	IT	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	IL	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	SK	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	TW	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	FR	AstraZeneca PLC	07 Nov 2023
Proteinuria	Phase 3	NL	AstraZeneca PLC	07 Nov 2023